<SEC-DOCUMENT>0001295345-16-000664.txt : 20160908
<SEC-HEADER>0001295345-16-000664.hdr.sgml : 20160908
<ACCEPTANCE-DATETIME>20160908162341
ACCESSION NUMBER:		0001295345-16-000664
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160908
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160908
DATE AS OF CHANGE:		20160908

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emerald Medical Applications Corp.
		CENTRAL INDEX KEY:			0000797542
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				680080601
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15746
		FILM NUMBER:		161876422

	BUSINESS ADDRESS:	
		STREET 1:		7 IMBER STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951141
		BUSINESS PHONE:		97237444505

	MAIL ADDRESS:	
		STREET 1:		7 IMBER STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951141

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZAXIS INTERNATIONAL INC
		DATE OF NAME CHANGE:	19950916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INFERGENE CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mrla8k09082016.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<body>
<div>

<hr SIZE="4" NOSHADE COLOR="#000000">

<p ALIGN="CENTER"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="4"><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br>
</b></font></p>

<p ALIGN="CENTER"><b><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="3">Washington, D.C.
20549<br>
</font></b></p>

<p ALIGN="CENTER"><font SIZE="4" FACE="Times New Roman, Times, Serif">___________________<br>
<br>
<strong>FORM 8-K<br>
</strong>___________________</font></p>

<p align="center"><font size="3"><b>CURRENT REPORT</b> </font></p>

<p align="center"><font size="2"><b>Pursuant to Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934</b> </font></p>

<p align="center"><font size="2">Date of report (date of earliest event reported):
August 31, 2016</font></p>

<p align="center">&nbsp;</p>

<p ALIGN="CENTER"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="5"><b><u>
EMERALD MEDICAL APPLICATIONS CORP.</u><br>
</b></font><font face="TIMES NEW ROMAN, TIMES, SERIF" size="1">(Exact Name of Registrant
as Specified in its Charter)</font></p>

<p ALIGN="CENTER">&nbsp;</p>

<p ALIGN="CENTER"><font size="2">Commission File No.: 0-15476</font></p>

<p ALIGN="CENTER">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td width="50%" align="center" style="height: 1px"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>Delaware</u></font></td>
    <td width="50%" align="center" style="height: 1px"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>68-0080601</u></font></td>
  </tr>
  <tr>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(State of Incorporation)</font></td>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(I.R.S. Employer
    Identification No.)</font></td>
  </tr>
  <tr>
    <td width="50%" align="center" style="height: 1px"><font size="1">&nbsp; </font></td>
    <td width="50%" align="center" style="height: 1px"><font size="1">&nbsp; </font></td>
  </tr>
  <tr>
    <td width="50%" align="center" style="height: 1px">
	<font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>7 Imber Street,
	Petach Tikva,
	Israel</u></font></td>
    <td width="50%" align="center" style="height: 1px">
	<font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>4951141</u></font></td>
  </tr>
  <tr>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(Address of Principal
    Executive Offices)</font></td>
    <td width="50%" align="center" bgcolor="#ffffff" style="height: 1px"><font size="1">(ZIP Code)</font></td>
  </tr>
</table>

<p>&nbsp;</p>

<p ALIGN="CENTER"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2">Registrant's
Telephone Number, including area code: (972) 3-744-4505</font></p>

<p ALIGN="CENTER">&nbsp;</p>

<p><font size="2">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below): </font></p>

<p><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Written communications
pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) <br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Soliciting material
pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Pre-commencement
communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Pre-commencement
communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</font></p>


<p Style='page-break-before:always'>

<hr SIZE="2" NOSHADE COLOR="#000000">

	<p><b><font size="2">Item 5.02 Departure of Directors or Certain Officers;
	Election of Directors; Appointment of Certain Officers; Compensatory
	Arrangements of Certain Officers</font></b></p>
	<p><font size="2">Effective on September 9, 2016 (the &quot;Effective Date&quot;) and
	subject to the acceptance of certain appointments and engagements as set
	forth below, the Board of Directors of Emerald Medical Applications Corp.
	(the &quot;Registrant&quot;) authorized the following executive appointments, changes
	in positions and resignations: (i) the appointment of Mr. Lior Wayn, the
	Registrant's CEO, CFO and a director, as president of the Registrant and of
	its wholly-owned Israeli subsidiary, Emerald Medical Applications Ltd
	(&quot;Emerald IL&quot;). In connection with Mr. Wayn's appointment as president of
	the Registrant and of Emerald IL, Mr. Wayn shall cease serving as CEO and
	CFO of the Registrant and of Emerald IL, as of the Effective Date, but shall
	remain as a member of the Board of Directors of both entities.</font></p>
	<p><font size="2">In connection with Mr. Wayn ceasing to serve as CEO and
	CFO of the Registrant and of Emerald IL, the Registrant: (i) appointed David
	Ben Naim, who had been appointed as financial controller of the Registrant
	and Emerald IL on June 15, 2016, as CFO of both entities; and (ii) appointed
	Mrs. Adi Zamir as CEO of the Registrant and of Emerald IL.</font></p>
	<p><font size="2"><i>Mrs. Adi Zamir, age 44, CEO:</i> Prior to her
	appointment as CEO of the Registrant, Mrs. Zamir served as VP of Product
	Development for Emerald IL. For the past 15 years prior to her appointment
	as CEO, Mrs. Zamir has developed significant mamanagement experience in
	charge of IT projects as well as extensive knowledge and experience in the
	implementation of international crowdsourcing projects in Israel. </font></p>
	<p><font size="2">From July 2007 until February 2011, Mrs. Zamir served as a
	director (business unit manager) and from March 2011 until May 2013 served
	as Vice President of the Training and Testing of Ness Technologies Inc.,
	formerly a reporting company listed on the Nasdaq and the Tel-Aviv Stock
	Exchange under the symbol NSTC. : NSTC and a leading Israeli ICT firm. From
	May 2013 until December 2014, Mrs. Zamir Adi served as the internation
	project leader for Israel's National Library - Information Systems Division,
	as well as serving as as an executive IT consultant to the Chief Executive
	Officers of several private companies in Israel.</font></p>
	<p><font size="2">Mrs. Zamir has a Masters in Law degree from Bar Ilan
	University, Ramat Gan, Israel, a Masters degree in Education - majoring in
	Cognition from The Hebrew University, Jerusalem, Israel and a B.Ed. in
	Science Education from Beit Berl College, Kfar Saba, Israel. From February
	2014 to the present, Mrs. Zamir has taught Information Systems Management at
	the Academic College of Tel Aviv-Yafo, Israel. </font></p>
	<p><font size="2">Professor Benad Goldwasser, who was appointed as a
	director of the Registrant and of Emerald IL on May 5, 2016, submitted his
	Letter of Resignation from both boards effective August 31, 2016. A copy of
	the Letter of Resignation is filed herewith as Exhibit 17.4. Professor
	Goldwasser had no disagreements with the operations, policies or practices
	of the Registrant or its subsidiary. In connection with the resignation of
	Professor Goldwasser, the Board of Directors appointed Mr. Chaim Hurvitz as
	a director.</font></p>
	<p><font size="2"><i>Chaim Hurvitz, age 56,director:</i> Mr. Hurvitz, who
	has over 30 years of experience in the life sciences industry, is the
	founder and has been CEO of CH Health-Private Venture Capital Ltd, a private
	venture capital firm, since its formation in May 2011. Since 2011, Mr.
	Hurvitz has served as Chairman of the Board of Directors of Galmed
	Pharmaceuticals Ltd, a public company organized under the laws of Israel (NasdaqCM:
	GLMD). From 2010 until July 2014, Mr. Hurvitz served as a member of the
	board of directors in Teva Pharmaceuticals Industries Ltd (NYSE: TEVA). Mr.
	Hurvitz was a member of the senior management of Teva Pharmaceuticals
	Industries Ltd., serving as the President of Teva International Group from
	2002 until 2010, as President and CEO of Teva Pharmaceuticals Europe from
	1992 to 1999 and as Vice President - TEVA Israeli Pharmaceutical Sales from
	1999 until 2002. Mr. Hurvitz is a member of the presidency board of the
	Manufacturers Association of Israel and chairs its pharmaceutical branch.
	Mr. Hurvitz received his Bachelor of Arts degree in political science and
	economics from Tel-Aviv Unitversity, Israel in 1985.</font></p>
	<font size="2" FACE="Times New Roman">
	<p ALIGN="JUSTIFY"><strong>Item 9.01 Financial Statements and Exhibits</strong></p>

<p align="justify">(b) The following documents are filed as exhibits to
this current report or incorporated by reference herein. Any document
incorporated by reference is identified by a parenthetical reference to the SEC filing
that included such document.</p>

<table ALIGN="CENTER" CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="100%" height="0%">
  <tr VALIGN="BOTTOM">
    <th height="0" bgcolor="#ffffff" style="width: 7%; height: 0%"><p align="left">
	<font SIZE="2">Exhibit
    No.</font></th>
    <th ALIGN="LEFT" height="0" bgcolor="#ffffff" style="width: 93">
	<font SIZE="2">Description</font></th>
  </tr>
  <tr>
    <td bgcolor="#FFFFFF" height="0%" style="width: 7%; height: 0"><font SIZE="2">17.4</font></td>
    <td bgcolor="#FFFFFF" height="0%" style="width: 93%; height: 0"><font SIZE="2">Letter of
	Resignation of Professor Benad Goldwasser dated August 31, 2016, filed
	herewith.</td>
  </tr>
</table>

	</font>
	<font size="2">
	<p style="text-align: center"><font size="2" face="Times New Roman">
	<font size="2">SIGNATURES</font></p>

<p ALIGN="JUSTIFY"><font size="2">Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></p>

<table ALIGN="CENTER" CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="100%">
  <tr VALIGN="TOP" BGCOLOR="#66FFFF">
    <td ALIGN="LEFT" WIDTH="100%" bgcolor="#FFFFFF"><div
    STYLE="MARGIN-LEFT: 11px; TEXT-INDENT: -10px"><u><p><i><font
    face="TIMES NEW ROMAN, TIMES, SERIF" size="2">/s/ Lior Wyan</font></i></u><br>
    <font size="2">CEO<br>
    	Lior Wyan<br>
    <i>&nbsp;&nbsp;</i>Date: September 8, 2016</font></p>
    </div></td>
  </tr>
</table>

	</font>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-17
<SEQUENCE>2
<FILENAME>exh17_4.htm
<DESCRIPTION>EXHIBIT 17.4
<TEXT>
<html>
<body>

<p><font size="2">
Exhibit 17.4</font></p>
<p style="text-align: center"><b><font size="2">
Professor Benad Goldwasser</font></b></p>
<p style="text-align: right"><font size="2">
August 31, 2016</font></p>
<p><font size="2">
Emerald Medical Applications Corp.</font></p>
<p><font size="2">
Board of Directors&nbsp;<br />
Yair Fudim, Chairman and<br />
Lior Wayn, Baruch Kfir and<br />
Dr. Estery Giloz-Ran, Directors<br />
&nbsp;<br />
Re: Letter of Resignation<br />
&nbsp;<br />
I hereby resign as a director of Emerald Medical Applications Corp. (the
&quot;Registrant&quot;) and its Israeli subsidiary, Emerald Medical Applications Ltd.. The
reason for my resignation is to permit me to pursue other business and
professional interests. I wish all of you at Emerald the very best success in
the future.<br />
&nbsp;<br />
I have had not disagreements with the operations, policies or practices of the
Registrant or its subsidiary.<br />
&nbsp;<br />
Yours truly,<br />
&nbsp;<br />
<i>/s/: Benad Goldwasser</i><br />
Professor Benad Goldwasser</p>

</body>

</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
